All Stories

  1. Neoadjuvant FOLFOXIRI plus bevacizumab without radiotherapy for high-risk rectal cancer: multicentre phase II trial

    Article • BJS Open, December 2025, Oxford University Press (OUP)

    Naomi Kiyota

  2. Nivolumab for platinum refractory salivary gland cancer

    Article • Japanese Journal of Clinical Oncology, December 2025, Oxford University Press (OUP)

    Naomi Kiyota

  3. Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review

    Article • Oral Oncology, October 2025, Elsevier

    Naomi Kiyota

  4. Corrigendum to: A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF -Mutated Thyroid Cancer in Japan

    Article • Thyroid, October 2025, SAGE Publications

    Naomi Kiyota

  5. Caution Needed Before Adopting Reduced-Dose Elective Neck Irradiation in Head and Neck Cancer: A Response to UPGRADE-RT

    Article • Journal of Clinical Oncology, July 2025, American Society of Clinical Oncology (ASCO)

    Naomi Kiyota

  6. Trastuzumab plus docetaxel is an effective treatment option for HER2 positive salivary gland cancer.

    Article • Japanese Journal of Clinical Oncology, June 2025, Oxford University Press (OUP)

    Naomi Kiyota

  7. Current treatment options and development for anaplastic thyroid cancer (ATC).

    Article • European Thyroid Journal, March 2025, Bioscientifica

    Naomi Kiyota

  8. Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome monitoring in patients with unresectable advanced cancers or metastatic/recurrent solid tumors

    Article • Japanese Journal of Clinical Oncology, February 2025, Oxford University Press (OUP)

    Naomi Kiyota

  9. Indications for chemoradiotherapy in elderly patients with locally advanced head and neck cancer.

    Article • Frontiers in Oncology, January 2025, Frontiers

    Naomi Kiyota

  10. This the updated Japanese guidline for the management of thyroid cancer patients

    Article • Endocrine Journal, January 2025, Japan Endocrine Society

    Naomi Kiyota

  11. Retrospective study of definitive therapy for head and neck mucosal melanoma: The RESUME study

    Article • EJC Skin Cancer, January 2025, Elsevier

    Naomi Kiyota

  12. Patients with head and neck cancer unfit for cisplatin—what next?

    Article • The Lancet Oncology, December 2024, Elsevier

    Naomi Kiyota

  13. The Cancer-Specific Health Economic Measure QLU-C10D is Valid and Responsive for Assessing Health Utility in Patients with Thyroid Cancer

    Article • Thyroid, November 2024, Mary Ann Liebert Inc

    Naomi Kiyota

  14. The european organisation for research and treatment of cancer head and neck cancer module (EORTC QLQ-HN43): Estimates for minimal important difference and minimal important change

    Article • European Journal of Cancer, November 2024, Elsevier

    Naomi Kiyota

  15. Incidence of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer.

    Article • Oral Oncology, October 2024, Elsevier

    Naomi Kiyota

  16. Tumor immune microenvironment (TIME) in salivary gand cancer (SGC).

    Article • Asia-Pacific Journal of Clinical Oncology, September 2024, Wiley

    Naomi Kiyota

  17. Acute kidney injury impacted the OS for HNSCC patients undergoing postoperative chemoradiotherapy

    Article • Cancer Medicine, September 2024, Wiley

    Naomi Kiyota

  18. A risk prediction for cisplatin induced acute kidney injury in JCOG1008

    Article • Oral Oncology, July 2024, Elsevier

    Naomi Kiyota

  19. paclitaxel plus cetuximab for double refractory RMHNSCC

    Article • ESMO Open, June 2024, Elsevier

    Naomi Kiyota

  20. Patient-Reported Outcomes in Randomized Controlled Trials for Cancer Conducted in Japan

    Article • Cureus, May 2024, Springer Science + Business Media

    Naomi Kiyota

  21. Targeting Anterior Commissure Involvement with Hyperfractionated Radiotherapy for T1–T2 Squamous Cell Carcinoma of the Glottic Larynx

    Article • Cancers, May 2024, MDPI AG

    Naomi Kiyota

  22. Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database

    Article • European Journal of Cancer, May 2024, Elsevier

    Naomi Kiyota

  23. Encorafenib/binimetinib should be another treatment option for BRAF mutated thyroid cancer patients.

    Article • Thyroid, March 2024, Mary Ann Liebert Inc

    Naomi Kiyota

  24. Post operative treatment for locally advanced squamous cell carcinoma of head and neck.

    Article • Japanese Journal of Clinical Oncology, March 2024, Oxford University Press (OUP)

    Naomi Kiyota

  25. Long‐term health‐related quality of life in head and neck cancer survivors: A large multinational study

    Article • International Journal of Cancer, February 2024, Wiley

    Naomi Kiyota

  26. The impact of electronic versus paper-based data capture on data collection logistics and on missing scores in thyroid cancer patients

    Article • Endocrine, December 2023, Springer Science + Business Media

    Naomi Kiyota

  27. Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancer

    Article • July 2023, Research Square

    Naomi Kiyota

  28. Summary of Japanese clinical practice guidelines for head and neck cancer - 2022 update edited by the Japan society for head and neck cancer

    Article • Auris Nasus Larynx, July 2023, Elsevier

    Naomi Kiyota

  29. Weekly versus 3‐weekly cisplatin along with radiotherapy for locoregionally advanced non‐nasopharyngeal head and neck cancers: Is the equipoise in literature addressed yet?

    Article • Head & Neck, April 2023, Wiley

    Naomi Kiyota

  30. Serious Long-Term Effects of Head and Neck Cancer from the Survivors’ Point of View

    Article • Healthcare, March 2023, MDPI AG

    Naomi Kiyota, Professor Orlando Guntinas-Lichius

  31. Patient-reported outcome and quality of life research in clinical trials for cancer patients

    Article • Japanese Journal of Clinical Oncology, January 2023, Oxford University Press (OUP)

    Naomi Kiyota

  32. Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial

    Article • BMJ Open, November 2022, BMJ

    Naomi Kiyota

  33. Reply to V. Noronha et al

    Article • Journal of Clinical Oncology, September 2022, American Society of Clinical Oncology (ASCO)

    Naomi Kiyota

  34. Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)

    Article • European Journal of Cancer, September 2022, Elsevier

    Naomi Kiyota

  35. Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination

    Article • Vaccines, June 2022, MDPI AG

    Naomi Kiyota

  36. Blowing time ratio and high-resolution manometry to evaluate swallowing function of patients with oral and oropharyngeal cancer

    Article • Auris Nasus Larynx, June 2022, Elsevier

    Naomi Kiyota

  37. Transition of the PD‑1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re‑challenge

    Article • Molecular and Clinical Oncology, April 2022, Spandidos Publications

    Naomi Kiyota

  38. Impact of baseline tumor burden in patients with differentiated thyroid cancer

    Article • Cancer, April 2022, Wiley

    Naomi Kiyota

  39. Human papillomavirus-related oropharyngeal carcinoma

    Article • Japanese Journal of Clinical Oncology, April 2022, Oxford University Press (OUP)

    Naomi Kiyota

  40. Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer

    Article • Journal of Infection and Chemotherapy, April 2022, Elsevier

    Naomi Kiyota

  41. Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008)

    Article • Journal of Clinical Oncology, March 2022, American Society of Clinical Oncology (ASCO)

    Naomi Kiyota

  42. Identification of Breast Cancer Stem Cells Using a Newly Developed Long-acting Fluorescence Probe, C5S-A, Targeting ALDH1A1

    Article • Anticancer Research, February 2022, International Institute of Anticancer Research

    Naomi Kiyota

  43. Systemic therapy for salivary gland malignancy: current status and future perspectives

    Article • Japanese Journal of Clinical Oncology, February 2022, Oxford University Press (OUP)

    Naomi Kiyota

  44. Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141

    Article • The Oncologist, February 2022, Oxford University Press (OUP)

    Naomi Kiyota

  45. A phase I study of LCL161, a novel oral pan‐inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors

    Article • Asia-Pacific Journal of Clinical Oncology, January 2022, Wiley

    Naomi Kiyota

  46. Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial

    Article • International Journal of Hematology, January 2022, Springer Science + Business Media

    Naomi Kiyota

  47. Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody

    Article • International Journal of Hematology, January 2022, Springer Science + Business Media

    Naomi Kiyota

  48. OUP accepted manuscript

    Article • Japanese Journal of Clinical Oncology, January 2022, Oxford University Press (OUP)

    Naomi Kiyota

  49. Severe and delayed-onset acneiform eruptions as an adverse reaction to regorafenib

    Article • Dermatology Reports, January 2022, PAGEPress Publications

    Naomi Kiyota

  50. Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

    Article • ESMO Open, December 2021, Elsevier

    Naomi Kiyota

  51. Roles of skull base surgery and particle radiotherapy for orbital malignant tumors involving the skull base

    Article • Laryngoscope Investigative Otolaryngology, October 2021, Wiley

    Naomi Kiyota

  52. Severe and delayed-onset acneiform eruptions as an adverse reaction to regorafenib

    Article • Dermatology Reports, October 2021, PAGEPress Publications

    Naomi Kiyota

  53. Safety and Immunogenicity of the COVID-19 Vaccine BNT162b2 in Patients Undergoing Chemotherapy for Solid Cancer

    Article • October 2021, Cold Spring Harbor Laboratory Press

    Naomi Kiyota

  54. Docetaxel plus cisplatin for non-squamous cell carcinoma of the head and neck

    Article • Medical Oncology, September 2021, Springer Science + Business Media

    Naomi Kiyota

  55. Minimal Important Difference and Minimal Important Change scores in EORTC QLQ-HN43

    Article • Quality of Life Research, July 2021, Springer Science + Business Media

    Naomi Kiyota

  56. Explore the optimal tumor burden for starting lenvatinib for differentiated thyroid cancer

    Article • Frontiers in Oncology, July 2021, Frontiers

    Naomi Kiyota

  57. Real-world data of nivolumab for recurrent or metastatic head and neck cancer in Japan

    Article • International Journal of Clinical Oncology, June 2021, Springer Science + Business Media

    Naomi Kiyota

  58. Guidelines for clinical evaluation of anti‐cancer drugs in Japan

    Article • Cancer Science, June 2021, Wiley

    Naomi Kiyota

  59. Incidence of cancer associated venous thromboembolism in Japan

    Article • International Journal of Hematology, June 2021, Springer Science + Business Media

    Naomi Kiyota

  60. Interpretation of the results of KEYNOTE-181 Study of Pembrolizumab for Esophageal Cancer

    Article • Journal of Clinical Oncology, April 2021, American Society of Clinical Oncology (ASCO)

    Naomi Kiyota

  61. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer

    Article • European Journal of Cancer, April 2021, Elsevier

    Naomi Kiyota

  62. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio With Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated With Lenvatinib

    Article • Thyroid, February 2021, Mary Ann Liebert Inc

    Naomi Kiyota

  63. Secondary CIC‑rearranged sarcoma responsive to chemotherapy regimens for Ewing sarcoma: A case report

    Article • Molecular and Clinical Oncology, February 2021, Spandidos Publications

    Naomi Kiyota

  64. Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse Events

    Article • Anticancer Research, January 2021, International Institute of Anticancer Research

    Naomi Kiyota

  65. Risk factors for osteoradionecrosis of the jaw in patients with head and neck squamous cell carcinoma

    Article • Radiation Oncology, January 2021, Springer Science + Business Media

    Naomi Kiyota

  66. Microsatellite instability-high colorectal cancer patient-derived xenograft models for cancer immunity research

    Article • Journal of Cancer Research and Therapeutics, January 2021, Medknow

    Naomi Kiyota

  67. Phase 1 Trial of Anti-PD-1 Ab of Spartalizumab for Japanese Cancer Patients

    Article • Cancer Science, December 2020, Wiley

    Naomi Kiyota

  68. Regorafenib‑induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report

    Article • Molecular and Clinical Oncology, December 2020, Spandidos Publications

    Naomi Kiyota

  69. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck

    Article • Japanese Journal of Clinical Oncology, December 2020, Oxford University Press (OUP)

    Naomi Kiyota

  70. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1)

    Article • International Journal of Clinical Oncology, November 2020, Springer Science + Business Media

    Naomi Kiyota

  71. Relationship between PDGFR expression and the response to pazopanib in intimal sarcoma of the pulmonary artery: A case report

    Article • Molecular and Clinical Oncology, November 2020, Spandidos Publications

    Naomi Kiyota

  72. Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial)

    Article • Cancer Chemotherapy and Pharmacology, October 2020, Springer Science + Business Media

    Naomi Kiyota

  73. Quality of Life in Patients With Hypoparathyroidism After Treatment for Thyroid Cancer

    Article • The Journal of Clinical Endocrinology & Metabolism, September 2020, Endocrine Society

    Naomi Kiyota

  74. Collaboration with EORTC QOL group and JCOG for PRO/QOL research

    Article • Japanese Journal of Clinical Oncology, August 2020, Oxford University Press (OUP)

    Naomi Kiyota

  75. Immunotherapy for squamous cell carcinoma of the head and neck

    Article • Japanese Journal of Clinical Oncology, August 2020, Oxford University Press (OUP)

    Naomi Kiyota

  76. Multi‐institutional Survey of Squamous Cell Carcinoma of the External Auditory Canal in Japan

    Article • The Laryngoscope, July 2020, Wiley

    Naomi Kiyota

  77. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan

    Article • Advances in Therapy, July 2020, Springer Science + Business Media

    Naomi Kiyota

  78. Long-term Follow-up Data of Nivolumab for Platinum Refractory Head and Neck Cancer in Asia

    Article • Head & Neck, June 2020, Wiley

    Naomi Kiyota

  79. First line pembrolizumab for recurrent or metastatic head and neck cancer

    Article • Therapeutic Radiology and Oncology, June 2020, AME Publishing Company

    Naomi Kiyota

  80. Ibuprofen gargle for chemo- or Chemoradiotherapy-induced Oral Mucositis: a feasibility study

    Article • Journal of Pharmaceutical Health Care and Sciences, June 2020, Springer Science + Business Media

    Naomi Kiyota

  81. The relationship between tumor burden and efficacy of nivolumab in head and neck cancer

    Article • International Journal of Clinical Oncology, April 2020, Springer Science + Business Media

    Naomi Kiyota

  82. Nutritional support dependence after curative chemoradiotherapy in head and neck cancer: supplementary analysis of a phase II trial (JCOG0706S1)

    Article • Japanese Journal of Clinical Oncology, October 2019, Oxford University Press (OUP)

    Naomi Kiyota

  83. Control of Lung Metastases and Colon Polyposis with Lenvatinib Therapy in a Patient with Cribriform-Morular Variant of Papillary Thyroid Carcinoma and an APC Gene Mutation: A Case Study

    Article • Thyroid, October 2019, Mary Ann Liebert Inc

    Naomi Kiyota

  84. Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age

    Article • Oral Oncology, September 2019, Elsevier

    Naomi Kiyota

  85. Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

    Article • JAMA Oncology, August 2019, American Medical Association (AMA)

    Naomi Kiyota, Professor Orlando Guntinas-Lichius

  86. A review of head and neck cancer staging system in the TNM classification of malignant tumors (eighth edition)

    Article • Japanese Journal of Clinical Oncology, June 2019, Oxford University Press (OUP)

    Naomi Kiyota

  87. Prognostic factors for Lenvatinib in radioiodine-refractory differentiated thyroid cancer (RR-DTC)

    Article • Head & Neck, April 2019, Wiley

    Naomi Kiyota

  88. PK study of S-1 in patients with renal impairment

    Article • Cancer Science, April 2019, Wiley

    Naomi Kiyota

  89. Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti‐Epidermal Growth Factor Receptor‐Induced Acne‐Like Rash: A Randomized Left‐Right Comparative Evaluation (APPEARANCE)

    Article • The Oncologist, March 2019, Alphamed Press

    Naomi Kiyota

  90. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer

    Article • Future Oncology, March 2019, Future Medicine

    Naomi Kiyota

  91. Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer

    Article • Frontiers in Oncology, February 2019, Frontiers

    Naomi Kiyota

  92. A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)

    Article • Frontiers in Oncology, January 2019, Frontiers

    Naomi Kiyota

  93. Controversies in relation to neck management in N0 early oral tongue cancer

    Article • Japanese Journal of Clinical Oncology, January 2019, Oxford University Press (OUP)

    Naomi Kiyota

  94. International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV

    Article • Head & Neck, January 2019, Wiley

    Naomi Kiyota

  95. Impact of retropharyngeal lymph node dissection in the surgical treatment of hypopharyngeal cancer

    Article • Head & Neck, January 2019, Wiley

    Naomi Kiyota

  96. Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia

    Article • Journal of Oncology Pharmacy Practice, December 2018, SAGE Publications

    Naomi Kiyota

  97. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria

    Article • Auris Nasus Larynx, December 2018, Elsevier

    Naomi Kiyota

  98. Thrombotic Microangiopathy by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Cancer

    Article • Case Reports in Oncology, November 2018, Karger Publishers

    Naomi Kiyota

  99. Clinical impact of cachexia in unresectable locally advanced head and neck cancer: supplementary analysis of a phase II trial (JCOG0706-S2)

    Article • Japanese Journal of Clinical Oncology, October 2018, Oxford University Press (OUP)

    Naomi Kiyota

  100. Randomized phase III study to evaluate the value of omission of prophylactic neck dissection for stage I/II tongue cancer: Japan Clinical Oncology Group study (JCOG1601, RESPOND)

    Article • Japanese Journal of Clinical Oncology, October 2018, Oxford University Press (OUP)

    Naomi Kiyota

  101. Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin

    Article • Oncogene, September 2018, Springer Science + Business Media

    Naomi Kiyota

  102. Role of intensive nutrition support and prophylactic percutaneous endoscopic gastrostomy during concomitant chemoradiotherapy for oropharyngeal cancer

    Article • International Journal of Clinical Oncology, August 2018, Springer Science + Business Media

    Naomi Kiyota

  103. CheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as First‐Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

    Article • The Oncologist, June 2018, Alphamed Press

    Naomi Kiyota

  104. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

    Article • Oral Oncology, June 2018, Elsevier

    Naomi Kiyota

  105. Adapalene gel 0.1% vs. placebo as prophylaxis for anti-EGFR-induced acne-like rash: A randomized left-right comparative evaluation (APPEARANCE).

    Article • Journal of Clinical Oncology, May 2018, American Society of Clinical Oncology (ASCO)

    Naomi Kiyota

  106. 3D Culture Represents Apoptosis Induced by Trastuzumab Better than 2D Monolayer Culture

    Article • Anticancer Research, May 2018, International Institute of Anticancer Research

    Naomi Kiyota

  107. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)

    Article • Cancer, April 2018, Wiley

    Naomi Kiyota

  108. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)

    Article • Annals of Oncology, April 2018, Elsevier

    Naomi Kiyota

  109. Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging

    Article • Oncotarget, March 2018, Impact Journals, LLC

    Naomi Kiyota

  110. Three-weekly cisplatin or weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma—the jury is still out

    Article • Therapeutic Radiology and Oncology, January 2018, AME Publishing Company

    Naomi Kiyota

  111. Immune check point inhibitors for head and neck cancer

    Article • Toukeibu Gan, January 2018, Japan Society for Head and Neck Cancer

    Naomi Kiyota

  112. Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis

    Article • Oral Oncology, January 2018, Elsevier

    Naomi Kiyota

  113. Prognostic value of ALDH2 polymorphism for patients with oropharyngeal cancer in a Japanese population

    Article • PLOS One, December 2017, PLOS

    Naomi Kiyota

  114. Expression of programmed death-1 in sentinel lymph nodes of breast cancer

    Article • Journal of Surgical Oncology, November 2017, Wiley

    Naomi Kiyota

  115. Optimal use of lenvatinib in the treatment of advanced thyroid cancer

    Article • Cancers of the Head & Neck, October 2017, Springer Science + Business Media

    Naomi Kiyota

  116. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141

    Article • Oral Oncology, October 2017, Elsevier

    Naomi Kiyota

  117. Prospective Cohort Study of Performance Status and Activities of Daily Living After Surgery for Spinal Metastasis

    Article • Clinical Spine Surgery A Spine Publication, October 2017, Wolters Kluwer Health

    Naomi Kiyota

  118. The validity of the definition of radioiodine refractory thyroid cancer

    Article • Thyroid, September 2017, Mary Ann Liebert Inc

    Naomi Kiyota

  119. Japanese Clinical Practice Guideline for Head and Neck Cancer

    Article • Auris Nasus Larynx, August 2017, Elsevier

    Naomi Kiyota

  120. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

    Article • The Lancet Oncology, August 2017, Elsevier

    Naomi Kiyota

  121. Weekly Low‐Dose Versus Three‐Weekly High‐Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non‐Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta‐Analysis of Aggregate Data

    Article • The Oncologist, May 2017, Alphamed Press

    Naomi Kiyota

  122. Quality of life and cost-utility of surgical treatment for patients with spinal metastases: prospective cohort study

    Article • International Orthopaedics, April 2017, Springer Science + Business Media

    Naomi Kiyota

  123. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid

    Article • European Journal of Cancer, April 2017, Elsevier

    Naomi Kiyota

  124. Lenvatinib for Anaplastic Thyroid Cancer

    Article • Frontiers in Oncology, March 2017, Frontiers

    Naomi Kiyota

  125. Long-term survival of a patient with metastatic melanoma treated with nivolumab and vemurafenib, with the development of vitiligo

    Article • European Journal of Dermatology, March 2017, John Libbey Eurotext

    Naomi Kiyota

  126. The EORTC module for quality of life in patients with thyroid cancer: phase III

    Article • Endocrine Related Cancer, February 2017, Bioscientifica

    Naomi Kiyota

  127. Multicenter Phase 2 Study of Cisplatin and 5-Fluorouracil With Concurrent Radiation Therapy as an Organ Preservation Approach in Patients With Squamous Cell Carcinoma of the Cervical Esophagus

    Article • International Journal of Radiation Oncology*Biology*Physics, December 2016, Elsevier

    Naomi Kiyota

  128. Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer

    Article • Auris Nasus Larynx, December 2016, Elsevier

    Naomi Kiyota

  129. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, November 2016, New England Journal of Medicine (NEJM/MMS)

    Naomi Kiyota

  130. Quality-of-Life Priorities in Patients with Thyroid Cancer: A Multinational European Organisation for Research and Treatment of Cancer Phase I Study

    Article • Thyroid, November 2016, Mary Ann Liebert Inc

    Naomi Kiyota

  131. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma

    Article • Cancer Chemotherapy and Pharmacology, May 2016, Springer Science + Business Media

    Naomi Kiyota

  132. A prospective study on the efficacy of two-dose influenza vaccinations in cancer patients receiving chemotherapy

    Article • Japanese Journal of Clinical Oncology, May 2016, Oxford University Press (OUP)

    Naomi Kiyota

  133. The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer

    Article • Cancer Chemotherapy and Pharmacology, April 2016, Springer Science + Business Media

    Naomi Kiyota

  134. Validity of new methods to evaluate renal function in cancer patients treated with cisplatin

    Article • Cancer Chemotherapy and Pharmacology, January 2016, Springer Science + Business Media

    Naomi Kiyota

  135. First-line chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma with or without cetuximab: a single institution experience

    Article • Toukeibu Gan, January 2016, Japan Society for Head and Neck Cancer

    Naomi Kiyota

  136. Treatment outcome of 72 patients with parotid cancer

    Article • Toukeibu Gan, January 2016, Japan Society for Head and Neck Cancer

    Naomi Kiyota

  137. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer

    Article • Cancer Science, November 2015, Wiley

    Naomi Kiyota

  138. Mediastinal Germ Cell Tumor Exhibiting a Discrepancy between Tumor Markers and Imaging: A Case Study

    Article • Case Reports in Oncology, August 2015, Karger Publishers

    Naomi Kiyota

  139. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT

    Article • European Radiology, July 2015, Springer Science + Business Media

    Naomi Kiyota

  140. Concomitant chemoradiotherapy for advanced squamous cell carcinoma of the temporal bone

    Article • Head & Neck, July 2015, Wiley

    Naomi Kiyota

  141. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

    Article • The Lancet Oncology, May 2015, Elsevier

    Naomi Kiyota, Professor Orlando Guntinas-Lichius, Professor Lena Specht

  142. Phase II trial of chemoradiotherapy with S‐1 plus cisplatin for unresectable locally advanced head and neck cancer ( JCOG 0706)

    Article • Cancer Science, April 2015, Wiley

    Naomi Kiyota

  143. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, February 2015, New England Journal of Medicine (NEJM/MMS)

    Naomi Kiyota

  144. Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer

    Article • Oncology Reports, January 2015, Spandidos Publications

    Naomi Kiyota

  145. Metabolomics Evaluation of Serum Markers for Cachexia and Their Intra-Day Variation in Patients with Advanced Pancreatic Cancer

    Article • PLOS One, November 2014, PLOS

    Naomi Kiyota

  146. Adjuvant treatment for post-operative head and neck squamous cell carcinoma

    Article • Japanese Journal of Clinical Oncology, November 2014, Oxford University Press (OUP)

    Naomi Kiyota

  147. Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients

    Article • PLOS One, August 2014, PLOS

    Naomi Kiyota

  148. Regulation of MET Kinase Inhibitor Resistance by Copy Number of MET in Gastric Carcinoma Cells

    Article • Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, July 2014, Cognizant Communication Corporation

    Naomi Kiyota

  149. Measuring quality of life in patients with head and neck cancer: Update of the EORTC QLQ-H&N Module, Phase III

    Article • Head & Neck, July 2014, Wiley

    Naomi Kiyota, Professor Orlando Guntinas-Lichius

  150. Randomized Phase II/III Trial of Post-operative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with Squamous Cell Carcinoma of Head and Neck: Japan Clinical Oncology Group Study (JCOG1008)

    Article • Japanese Journal of Clinical Oncology, May 2014, Oxford University Press (OUP)

    Naomi Kiyota

  151. Prognostic Value of FDG PET Imaging in Patients with Laryngeal Cancer

    Article • PLOS One, May 2014, PLOS

    Naomi Kiyota

  152. Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide

    Article • Clinical Journal of Gastroenterology, April 2014, Springer Science + Business Media

    Naomi Kiyota

  153. Role of the medical oncologist in multi-disciplinary treatment for head and neck cancer

    Article • Toukeibu Gan, January 2014, Japan Society for Head and Neck Cancer

    Naomi Kiyota

  154. Safety profile and efficacy of Chemotherapy with Docetaxel and Cisplatin (DC) for Recurrent or Metastatic Head and Neck Cancer^|^ndash;A Retrospective Analysis in a Single Institution

    Article • Toukeibu Gan, January 2014, Japan Society for Head and Neck Cancer

    Naomi Kiyota

  155. Therapeutic strategy for advanced laryngeal and hypopharyngeal cancer

    Article • Toukeibu Gan, January 2014, Japan Society for Head and Neck Cancer

    Naomi Kiyota

  156. Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines

    Article • Oncology Reports, July 2013, Spandidos Publications

    Naomi Kiyota

  157. Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line

    Article • Investigational New Drugs, April 2013, Springer Science + Business Media

    Naomi Kiyota

  158. A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer

    Article • Gastric Cancer, March 2013, Springer Science + Business Media

    Naomi Kiyota

  159. A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors

    Article • Cancer Chemotherapy and Pharmacology, February 2013, Springer Science + Business Media

    Naomi Kiyota

  160. Prediction of Glomerular Filtration Rate in Cancer Patients by an Equation for Japanese Estimated Glomerular Filtration Rate

    Article • Japanese Journal of Clinical Oncology, January 2013, Oxford University Press (OUP)

    Naomi Kiyota

  161. Two cases of melanoma to cervical lymph nodes from an unknown primary site

    Article • Toukeibu Gan, January 2013, Japan Society for Head and Neck Cancer

    Naomi Kiyota

  162. Radiotherapy for Stage I or II hypopharyngeal carcinoma

    Article • Journal of Radiation Research, September 2012, Oxford University Press (OUP)

    Naomi Kiyota

  163. Phase II Feasibility Trial of Adjuvant Chemoradiotherapy with 3-weekly Cisplatin for Japanese Patients with Post-operative High-risk Squamous Cell Carcinoma of the Head and Neck

    Article • Japanese Journal of Clinical Oncology, August 2012, Oxford University Press (OUP)

    Naomi Kiyota

  164. Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line

    Article • Investigational New Drugs, July 2012, Springer Science + Business Media

    Naomi Kiyota

  165. Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification

    Article • International Journal of Oncology, May 2012, Spandidos Publications

    Naomi Kiyota

  166. A safety profile of sequential therapy for unresectable head and neck cancer: A retrospective analysis in a single institution

    Article • Toukeibu Gan, January 2012, Japan Society for Head and Neck Cancer

    Naomi Kiyota

  167. Understanding the characteristics of molecular targeting agents for proper usage

    Article • Toukeibu Gan, January 2012, Japan Society for Head and Neck Cancer

    Naomi Kiyota

  168. Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors

    Article • Investigational New Drugs, October 2011, Springer Science + Business Media

    Naomi Kiyota

  169. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks

    Article • Investigational New Drugs, June 2011, Springer Science + Business Media

    Naomi Kiyota

  170. Successful neutrophil engraftment by reduced use of granulocyte colony-stimulating factor after allogeneic hematopoietic stem cell transplantation with mycophenolate mofetil for graft-versus-host disease prophylaxis

    Article • International Journal of Hematology, April 2011, Springer Science + Business Media

    Naomi Kiyota

  171. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients

    Article • Investigational New Drugs, February 2011, Springer Science + Business Media

    Naomi Kiyota

  172. Approaches to encourage broad use of adjuvant chemoradiotherapy for postoperative high-risk patients with squamous cell carcinoma of the head and neck in Japan

    Article • Toukeibu Gan, January 2011, Japan Society for Head and Neck Cancer

    Naomi Kiyota

  173. Post-operative radiation therapy for locally advanced hypopharyngeal carcinoma

    Article • Toukeibu Gan, January 2011, Japan Society for Head and Neck Cancer

    Naomi Kiyota

  174. Left atrial extension of metastatic lung tumor via pulmonary vein: report on the first case of Ewing sarcoma

    Article • Rare Tumors, August 2010, PAGEPress Publications

    Naomi Kiyota

  175. Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer

    Article • Annals of Oncology, June 2010, Oxford University Press (OUP)

    Naomi Kiyota

  176. Future perspectives in head and neck oncology in Japan -Current status and challenges facing clinical trials for head and neck oncology in Japan-

    Article • Toukeibu Gan, January 2010, Japan Society for Head and Neck Cancer

    Naomi Kiyota

  177. Phase II Trial of Concurrent Chemoradiotherapy with S-1 Plus Cisplatin in Patients with Unresectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Japan Clinical Oncology Group Study (JCOG0706)

    Article • Japanese Journal of Clinical Oncology, May 2009, Oxford University Press (OUP)

    Naomi Kiyota

  178. Systemic Chemotherapy with Cisplatin Plus 5-FU (PF) for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): Efficacy and Safety of a Lower Dose of PF (80/800) at a Single Institution in Japan

    Article • Japanese Journal of Clinical Oncology, February 2009, Oxford University Press (OUP)

    Naomi Kiyota

  179. Effectiveness of prophylactic percutaneous endoscopic gastrostomy for oropharyngeal cancer patients undergoing concurrent chemoradiotherapy

    Article • Toukeibu Gan, January 2009, Japan Society for Head and Neck Cancer

    Naomi Kiyota

  180. Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma

    Article • Cancer, January 2008, Wiley

    Naomi Kiyota

  181. Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan

    Article • Alimentary Pharmacology & Therapeutics, February 2007, Wiley

    Naomi Kiyota

  182. Influence of cure of Helicobacter pylori infection on gastric acidity and gastroesophageal reflux: study by 24-h pH monitoring in patients with gastric or duodenal ulcer

    Article • Journal of Gastroenterology, May 2005, Springer Science + Business Media

    Naomi Kiyota